Inverness Counsel’s Johnson & Johnson JNJ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $41.2M | Sell |
252,178
-7,293
| -3% | -$1.23M | 2.29% | 10 |
|
|
2022
Q2 | $46.1M | Buy |
259,471
+3,697
| +1% | +$659K | 2.58% | 11 |
|
|
2022
Q1 | $45.3M | Buy |
255,774
+161,813
| +172% | +$27.5M | 2.03% | 15 |
|
|
2021
Q4 | $16.1M | Sell |
93,961
-24,062
| -20% | -$3.94M | 0.59% | 39 |
|
|
2021
Q3 | $19.1M | Buy |
118,023
+61,561
| +109% | +$10.5M | 0.7% | 39 |
|
|
2021
Q2 | $9.3M | Sell |
56,462
-28,323
| -33% | -$4.69M | 0.34% | 53 |
|
|
2021
Q1 | $13.9M | Sell |
84,785
-215,703
| -72% | -$34.9M | 0.58% | 45 |
|
|
2020
Q4 | $47.3M | Sell |
300,488
-16,073
| -5% | -$2.37M | 1.93% | 19 |
|
|
2020
Q3 | $47.1M | Buy |
316,561
+3,210
| +1% | +$475K | 2.11% | 17 |
|
|
2020
Q2 | $44.1M | Buy |
313,351
+4,841
| +2% | +$705K | 2.19% | 11 |
|
|
2020
Q1 | $40.5M | Sell |
308,510
-31,521
| -9% | -$4.47M | 2.54% | 9 |
|
|
2019
Q4 | $49.6M | Buy |
340,031
+112,379
| +49% | +$15.2M | 2.34% | 12 |
|
|
2019
Q3 | $29.5M | Buy |
227,652
+43,569
| +24% | +$5.74M | 1.52% | 28 |
|
|
2019
Q2 | $25.6M | Buy |
184,083
+114,505
| +165% | +$15.8M | 1.31% | 32 |
|
|
2019
Q1 | $9.73M | Sell |
69,578
-1,515
| -2% | -$203K | 0.53% | 46 |
|
|
2018
Q4 | $9.17M | Buy |
71,093
+21,116
| +42% | +$2.95M | 0.61% | 43 |
|
|
2018
Q3 | $6.91M | Buy |
49,977
+1,054
| +2% | +$140K | 0.36% | 46 |
|
|
2018
Q2 | $5.94M | Sell |
48,923
-49,966
| -51% | -$6.23M | 0.34% | 45 |
|
|
2018
Q1 | $12.7M | Sell |
98,889
-12,203
| -11% | -$1.65M | 0.76% | 40 |
|
|
2017
Q4 | $15.5M | Buy |
111,092
+65,843
| +146% | +$9.17M | 0.97% | 41 |
|
|
2017
Q3 | $5.88M | Sell |
45,249
-534
| -1% | -$70.8K | 0.42% | 46 |
|
|
2017
Q2 | $6.06M | Sell |
45,783
-2,339
| -5% | -$298K | 0.42% | 49 |
|
|
2017
Q1 | $6.03M | Sell |
48,122
-1,100
| -2% | -$131K | 0.42% | 53 |
|
|
2016
Q4 | $5.57M | Sell |
49,222
-4,625
| -9% | -$534K | 0.42% | 52 |
|
|
2016
Q3 | $6.36M | Sell |
53,847
-405
| -0.7% | -$49.1K | 0.5% | 44 |
|
|
2016
Q2 | $6.58M | Buy |
54,252
+2,004
| +4% | +$228K | 0.51% | 43 |
|
|
2016
Q1 | $5.65M | Sell |
52,248
-3,900
| -7% | -$404K | 0.44% | 41 |
|
|
2015
Q4 | $5.77M | Sell |
56,148
-30,174
| -35% | -$3.03M | 0.44% | 44 |
|
|
2015
Q3 | $8.06M | Sell |
86,322
-33,681
| -28% | -$3.26M | 0.68% | 42 |
|
|
2015
Q2 | $11.7M | Sell |
120,003
-40,002
| -25% | -$4.01M | 0.85% | 41 |
|
|
2015
Q1 | $16.1M | Sell |
160,005
-55,932
| -26% | -$5.69M | 1.19% | 33 |
|
|
2014
Q4 | $22.6M | Buy |
215,937
+2,368
| +1% | +$250K | 1.73% | 22 |
|
|
2014
Q3 | $22.8M | Sell |
213,569
-16,705
| -7% | -$1.73M | 1.82% | 21 |
|
|
2014
Q2 | $24.1M | Buy |
230,274
+10,117
| +5% | +$1.02M | 1.88% | 16 |
|
|
2014
Q1 | $21.6M | Buy |
220,157
+91,110
| +71% | +$8.45M | 1.72% | 25 |
|
|
2013
Q4 | $11.8M | Buy |
129,047
+740
| +0.6% | +$68.2K | 0.94% | 38 |
|
|
2013
Q3 | $11.1M | Sell |
128,307
-5,800
| -4% | -$520K | 0.95% | 38 |
|
|
2013
Q2 | $11.5M | Buy |
+134,107
| New | +$11.4M | 1.03% | 38 |
|
Other funds holding JNJ
Inverness Counsel's JNJ Position: Q3 2022 in Review
Inverness Counsel reduced its Johnson & Johnson (JNJ) stake by 2.8% in Q3 2022, selling an estimated $1.23M and leaving 252,178 shares worth $41.2M. The position accounts for 2.29% of the portfolio, ranked #10.
Inverness Counsel first reported a position in JNJ in Q2 2013 and has held it in 38 quarters since. The position peaked at $49.6M in Q4 2019. 3,624 funds tracked by Wall St. Rank hold JNJ as of Q3 2022.
- Inverness Counsel held 252,178 shares of Johnson & Johnson worth $41.2M as of Q3 2022.
- Inverness Counsel sold 7,293 Johnson & Johnson shares in Q3 2022, an estimated $1.23M.
- Johnson & Johnson made up 2.29% of Inverness Counsel's portfolio in Q3 2022, its #10 holding.
- Inverness Counsel first reported a position in Johnson & Johnson in Q2 2013 and has held it in 38 quarters since.
- Inverness Counsel's Johnson & Johnson position peaked at $49.6M in Q4 2019.
- 3,624 funds tracked by Wall St. Rank held Johnson & Johnson as of Q3 2022.
Based on Inverness Counsel's 13F filing for Q3 2022, filed 26 Oct 2022.